Show simple item record

dc.contributor.authorPost, C. C. B.
dc.contributor.authorde Boer, S. M.
dc.contributor.authorPowell, M. E.
dc.contributor.authorMileshkin, L.
dc.contributor.authorKatsaros, D.
dc.contributor.authorBessette, P.
dc.contributor.authorHaie-Meder, C.
dc.contributor.authorOttevanger, N. P. B.
dc.contributor.authorLedermann, J. A.
dc.contributor.authorKhaw, P.
dc.contributor.authorD'Amico, R.
dc.contributor.authorFyles, A.
dc.contributor.authorBaron, M. H.
dc.contributor.authorKitchener, Henry C
dc.contributor.authorNijman, H. W.
dc.contributor.authorLutgens, L.
dc.contributor.authorBrooks, S.
dc.contributor.authorJürgenliemk-Schulz, I. M.
dc.contributor.authorFeeney, A.
dc.contributor.authorGoss, G.
dc.contributor.authorFossati, R.
dc.contributor.authorGhatage, P.
dc.contributor.authorLeary, A.
dc.contributor.authorDo, V.
dc.contributor.authorLissoni, A. A.
dc.contributor.authorMcCormack, M.
dc.contributor.authorNout, R. A.
dc.contributor.authorVerhoeven-Adema, K. W.
dc.contributor.authorSmit, V.
dc.contributor.authorPutter, H.
dc.contributor.authorCreutzberg, C. L.
dc.date.accessioned2020-12-08T05:36:38Z
dc.date.available2020-12-08T05:36:38Z
dc.date.issued2020en
dc.identifier.citationPost CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, et al. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. Int J Radiat Oncol Biol Phys. 2020.en
dc.identifier.pmid33129910en
dc.identifier.doi10.1016/j.ijrobp.2020.10.030en
dc.identifier.urihttp://hdl.handle.net/10541/623533
dc.description.abstractBackground: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiotherapy versus pelvic radiotherapy alone. The present analysis was performed to compare long-term adverse events (AE) and health-related quality of life (HRQOL). Patients and methods: 660 women with high-risk endometrial cancer were randomly assigned to receive chemoradiotherapy (2 concurrent cycles of cisplatin followed by 4 cycles of carboplatin/paclitaxel) or radiotherapy alone. Toxicity was graded using CTCAE v3.0. HRQOL was measured using EORTC QLQ-C30 and CX24/OV28-subscales and compared to normative-data. An as-treated analysis was performed. Results: Median follow up was 74.6 months; 574 (87%) patients were evaluable for HRQOL. At 5 years, grade ≥2 AE were scored for 78 (38%) patients who had received chemoradiotherapy versus 46 (24%) who had received radiotherapy (p=0.008). Grade 3 AE did not differ significantly between the groups (8% vs 5%, p=0.18) at 5 years, and only one new late grade 4 toxicity had been reported. At 3 and 5 years, sensory neuropathy toxicity grade ≥2 persisted after chemoradiotherapy in 6% (vs 0% after radiotherapy, p<0.001) and more patients reported significant tingling or numbness at HRQOL (27% vs 8%, p<0.001 at 3 years; 24% vs 9%, p=0.002 at 5 years). Until 3 years, more patients who had chemoradiotherapy reported limb weakness (21% vs 5%, p<0.001) and lower physical (79 vs 87, p<0.001) and role functioning (78 vs 88, p<0.001) scores. Both treatment groups reported similar long-term global health/QOL scores, which were better than those of the normative-population. Conclusion: This study shows a long-lasting, clinically relevant, negative impact of chemoradiotherapy on toxicity and HRQOL, most importantly persistent peripheral sensory neuropathy. Physical and role functioning impairments were seen until 3 years. These long-term data are essential for patient information and shared decision-making regarding adjuvant chemotherapy for high-risk endometrial cancer.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ijrobp.2020.10.030en
dc.titleLong-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trialen
dc.typeArticleen
dc.contributor.departmentRadiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.en
dc.identifier.journalInternational Journal of Radiation Oncology Biology Physicsen
dc.description.noteen]
refterms.dateFOA2020-12-08T14:43:05Z


Files in this item

Thumbnail
Name:
33129910.pdf
Size:
474.9Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record